Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Morton’s Neuroma

Centrexion Therapeutics, a company focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-opioid therapies in active development, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CNTX-4975 for the treatment of Morton’s neuroma, a rare, painful nerve disorder of the foot. CNTX-4975, Centrexion’s proprietary lead pipeline candidate, is a highly potent, ultrapure, synthetic form of capsaicin (originally derived from the chili plant), called trans-capsaicin, that is designed to be injected directly into the site of the pain to provide rapid onset analgesia and a long duration of relief.

This entry was posted in Recent Development News: Q4 - 2016, Recent Developments. Bookmark the permalink.
Read Full Article »